Included in the analysis was a set of adenosine signature genes (Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Il8, Il1b, Ptgs2), which were recently summarized based on RCC treatment-naïve patients (Fong et al., 2020). This evidence concerns the gene CXCL2 and renal cell carcinoma.